nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4A—decidua—ovarian cancer	0.00925	0.104	CbGeAlD
Roflumilast—PDE4D—female gonad—ovarian cancer	0.00748	0.0844	CbGeAlD
Roflumilast—PDE4D—testis—ovarian cancer	0.00663	0.0748	CbGeAlD
Roflumilast—PDE4A—female gonad—ovarian cancer	0.00662	0.0747	CbGeAlD
Roflumilast—PDE4A—testis—ovarian cancer	0.00587	0.0662	CbGeAlD
Roflumilast—PDE4B—uterine cervix—ovarian cancer	0.00579	0.0653	CbGeAlD
Roflumilast—PDE4B—decidua—ovarian cancer	0.00552	0.0622	CbGeAlD
Roflumilast—PDE4B—endometrium—ovarian cancer	0.00524	0.0591	CbGeAlD
Roflumilast—PDE4B—gonad—ovarian cancer	0.00486	0.0548	CbGeAlD
Roflumilast—PDE4D—lymph node—ovarian cancer	0.00481	0.0542	CbGeAlD
Roflumilast—PDE4B—female reproductive system—ovarian cancer	0.00434	0.0489	CbGeAlD
Roflumilast—PDE4A—lymph node—ovarian cancer	0.00426	0.048	CbGeAlD
Roflumilast—PDE4B—bone marrow—ovarian cancer	0.00409	0.0462	CbGeAlD
Roflumilast—PDE4B—female gonad—ovarian cancer	0.00395	0.0445	CbGeAlD
Roflumilast—PDE4B—vagina—ovarian cancer	0.00392	0.0442	CbGeAlD
Roflumilast—PDE4B—testis—ovarian cancer	0.0035	0.0395	CbGeAlD
Roflumilast—Dyspepsia—Topotecan—ovarian cancer	0.00258	0.0029	CcSEcCtD
Roflumilast—Urinary tract infection—Paclitaxel—ovarian cancer	0.00257	0.00289	CcSEcCtD
Roflumilast—Decreased appetite—Topotecan—ovarian cancer	0.00255	0.00287	CcSEcCtD
Roflumilast—PDE4B—lymph node—ovarian cancer	0.00254	0.0286	CbGeAlD
Roflumilast—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00253	0.00285	CcSEcCtD
Roflumilast—Fatigue—Topotecan—ovarian cancer	0.00253	0.00284	CcSEcCtD
Roflumilast—Dyspepsia—Melphalan—ovarian cancer	0.00253	0.00284	CcSEcCtD
Roflumilast—Constipation—Topotecan—ovarian cancer	0.00251	0.00282	CcSEcCtD
Roflumilast—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.0025	0.00281	CcSEcCtD
Roflumilast—Decreased appetite—Melphalan—ovarian cancer	0.0025	0.00281	CcSEcCtD
Roflumilast—Infection—Vinorelbine—ovarian cancer	0.00249	0.0028	CcSEcCtD
Roflumilast—Sinusitis—Paclitaxel—ovarian cancer	0.00248	0.00279	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00248	0.00279	CcSEcCtD
Roflumilast—Fatigue—Melphalan—ovarian cancer	0.00248	0.00278	CcSEcCtD
Roflumilast—Nervous system disorder—Vinorelbine—ovarian cancer	0.00246	0.00277	CcSEcCtD
Roflumilast—Skin disorder—Vinorelbine—ovarian cancer	0.00244	0.00274	CcSEcCtD
Roflumilast—Hypersensitivity—Chlorambucil—ovarian cancer	0.00243	0.00273	CcSEcCtD
Roflumilast—Feeling abnormal—Topotecan—ovarian cancer	0.00242	0.00272	CcSEcCtD
Roflumilast—Gastrointestinal pain—Topotecan—ovarian cancer	0.0024	0.0027	CcSEcCtD
Roflumilast—Rhinitis—Paclitaxel—ovarian cancer	0.00238	0.00268	CcSEcCtD
Roflumilast—Asthenia—Chlorambucil—ovarian cancer	0.00236	0.00266	CcSEcCtD
Roflumilast—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00233	0.00262	CcSEcCtD
Roflumilast—Urticaria—Topotecan—ovarian cancer	0.00233	0.00262	CcSEcCtD
Roflumilast—Abdominal pain—Topotecan—ovarian cancer	0.00232	0.00261	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00229	0.00257	CcSEcCtD
Roflumilast—Urticaria—Melphalan—ovarian cancer	0.00228	0.00257	CcSEcCtD
Roflumilast—Weight decreased—Docetaxel—ovarian cancer	0.00227	0.00256	CcSEcCtD
Roflumilast—Pneumonia—Docetaxel—ovarian cancer	0.00226	0.00254	CcSEcCtD
Roflumilast—Diarrhoea—Chlorambucil—ovarian cancer	0.00225	0.00253	CcSEcCtD
Roflumilast—Infestation NOS—Docetaxel—ovarian cancer	0.00224	0.00252	CcSEcCtD
Roflumilast—Infestation—Docetaxel—ovarian cancer	0.00224	0.00252	CcSEcCtD
Roflumilast—Cardiac disorder—Paclitaxel—ovarian cancer	0.0022	0.00248	CcSEcCtD
Roflumilast—Decreased appetite—Vinorelbine—ovarian cancer	0.00218	0.00245	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00217	0.00244	CcSEcCtD
Roflumilast—Fatigue—Vinorelbine—ovarian cancer	0.00216	0.00243	CcSEcCtD
Roflumilast—Hypersensitivity—Topotecan—ovarian cancer	0.00216	0.00243	CcSEcCtD
Roflumilast—Constipation—Vinorelbine—ovarian cancer	0.00214	0.00241	CcSEcCtD
Roflumilast—Immune system disorder—Paclitaxel—ovarian cancer	0.00214	0.00241	CcSEcCtD
Roflumilast—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00214	0.00241	CcSEcCtD
Roflumilast—Renal failure acute—Epirubicin—ovarian cancer	0.00213	0.00239	CcSEcCtD
Roflumilast—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00212	0.00238	CcSEcCtD
Roflumilast—Hypersensitivity—Melphalan—ovarian cancer	0.00212	0.00238	CcSEcCtD
Roflumilast—Asthenia—Topotecan—ovarian cancer	0.0021	0.00237	CcSEcCtD
Roflumilast—Vomiting—Chlorambucil—ovarian cancer	0.00209	0.00236	CcSEcCtD
Roflumilast—Mental disorder—Paclitaxel—ovarian cancer	0.00208	0.00234	CcSEcCtD
Roflumilast—Malnutrition—Paclitaxel—ovarian cancer	0.00207	0.00232	CcSEcCtD
Roflumilast—Feeling abnormal—Vinorelbine—ovarian cancer	0.00207	0.00232	CcSEcCtD
Roflumilast—Asthenia—Melphalan—ovarian cancer	0.00206	0.00232	CcSEcCtD
Roflumilast—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00205	0.00231	CcSEcCtD
Roflumilast—Tension—Paclitaxel—ovarian cancer	0.00203	0.00228	CcSEcCtD
Roflumilast—Dysgeusia—Paclitaxel—ovarian cancer	0.00202	0.00228	CcSEcCtD
Roflumilast—Rhinitis—Docetaxel—ovarian cancer	0.00202	0.00227	CcSEcCtD
Roflumilast—Nervousness—Paclitaxel—ovarian cancer	0.00201	0.00226	CcSEcCtD
Roflumilast—Diarrhoea—Topotecan—ovarian cancer	0.00201	0.00226	CcSEcCtD
Roflumilast—Back pain—Paclitaxel—ovarian cancer	0.002	0.00225	CcSEcCtD
Roflumilast—Urticaria—Vinorelbine—ovarian cancer	0.00199	0.00224	CcSEcCtD
Roflumilast—Muscle spasms—Paclitaxel—ovarian cancer	0.00199	0.00224	CcSEcCtD
Roflumilast—Abdominal pain—Vinorelbine—ovarian cancer	0.00198	0.00223	CcSEcCtD
Roflumilast—Connective tissue disorder—Docetaxel—ovarian cancer	0.00198	0.00222	CcSEcCtD
Roflumilast—Renal failure acute—Doxorubicin—ovarian cancer	0.00197	0.00221	CcSEcCtD
Roflumilast—Diarrhoea—Melphalan—ovarian cancer	0.00196	0.00221	CcSEcCtD
Roflumilast—Nausea—Chlorambucil—ovarian cancer	0.00196	0.0022	CcSEcCtD
Roflumilast—Dizziness—Topotecan—ovarian cancer	0.00194	0.00218	CcSEcCtD
Roflumilast—Tremor—Paclitaxel—ovarian cancer	0.00194	0.00218	CcSEcCtD
Roflumilast—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00192	0.00216	CcSEcCtD
Roflumilast—Angioedema—Paclitaxel—ovarian cancer	0.00189	0.00212	CcSEcCtD
Roflumilast—Cardiac disorder—Docetaxel—ovarian cancer	0.00187	0.0021	CcSEcCtD
Roflumilast—Vomiting—Topotecan—ovarian cancer	0.00186	0.0021	CcSEcCtD
Roflumilast—Malaise—Paclitaxel—ovarian cancer	0.00186	0.0021	CcSEcCtD
Roflumilast—Vertigo—Paclitaxel—ovarian cancer	0.00186	0.00209	CcSEcCtD
Roflumilast—Rash—Topotecan—ovarian cancer	0.00185	0.00208	CcSEcCtD
Roflumilast—Hypersensitivity—Vinorelbine—ovarian cancer	0.00185	0.00208	CcSEcCtD
Roflumilast—Dermatitis—Topotecan—ovarian cancer	0.00185	0.00208	CcSEcCtD
Roflumilast—Headache—Topotecan—ovarian cancer	0.00184	0.00207	CcSEcCtD
Roflumilast—Palpitations—Paclitaxel—ovarian cancer	0.00183	0.00205	CcSEcCtD
Roflumilast—Vomiting—Melphalan—ovarian cancer	0.00183	0.00205	CcSEcCtD
Roflumilast—Immune system disorder—Docetaxel—ovarian cancer	0.00182	0.00204	CcSEcCtD
Roflumilast—Mediastinal disorder—Docetaxel—ovarian cancer	0.00181	0.00204	CcSEcCtD
Roflumilast—Rash—Melphalan—ovarian cancer	0.00181	0.00204	CcSEcCtD
Roflumilast—Dermatitis—Melphalan—ovarian cancer	0.00181	0.00203	CcSEcCtD
Roflumilast—Asthenia—Vinorelbine—ovarian cancer	0.0018	0.00202	CcSEcCtD
Roflumilast—Mental disorder—Docetaxel—ovarian cancer	0.00176	0.00198	CcSEcCtD
Roflumilast—Myalgia—Paclitaxel—ovarian cancer	0.00176	0.00198	CcSEcCtD
Roflumilast—Anxiety—Paclitaxel—ovarian cancer	0.00175	0.00197	CcSEcCtD
Roflumilast—Malnutrition—Docetaxel—ovarian cancer	0.00175	0.00197	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00175	0.00197	CcSEcCtD
Roflumilast—Nausea—Topotecan—ovarian cancer	0.00174	0.00196	CcSEcCtD
Roflumilast—Discomfort—Paclitaxel—ovarian cancer	0.00174	0.00196	CcSEcCtD
Roflumilast—Gastritis—Epirubicin—ovarian cancer	0.00174	0.00195	CcSEcCtD
Roflumilast—Diarrhoea—Vinorelbine—ovarian cancer	0.00172	0.00193	CcSEcCtD
Roflumilast—Dysgeusia—Docetaxel—ovarian cancer	0.00172	0.00193	CcSEcCtD
Roflumilast—Nausea—Melphalan—ovarian cancer	0.00171	0.00192	CcSEcCtD
Roflumilast—Influenza—Epirubicin—ovarian cancer	0.0017	0.00191	CcSEcCtD
Roflumilast—Back pain—Docetaxel—ovarian cancer	0.00169	0.00191	CcSEcCtD
Roflumilast—Muscle spasms—Docetaxel—ovarian cancer	0.00168	0.00189	CcSEcCtD
Roflumilast—Infection—Paclitaxel—ovarian cancer	0.00168	0.00189	CcSEcCtD
Roflumilast—Dizziness—Vinorelbine—ovarian cancer	0.00166	0.00187	CcSEcCtD
Roflumilast—Nervous system disorder—Paclitaxel—ovarian cancer	0.00165	0.00186	CcSEcCtD
Roflumilast—Skin disorder—Paclitaxel—ovarian cancer	0.00164	0.00184	CcSEcCtD
Roflumilast—Gastritis—Doxorubicin—ovarian cancer	0.00161	0.00181	CcSEcCtD
Roflumilast—Vomiting—Vinorelbine—ovarian cancer	0.00159	0.00179	CcSEcCtD
Roflumilast—Rash—Vinorelbine—ovarian cancer	0.00158	0.00178	CcSEcCtD
Roflumilast—Dermatitis—Vinorelbine—ovarian cancer	0.00158	0.00178	CcSEcCtD
Roflumilast—Headache—Vinorelbine—ovarian cancer	0.00157	0.00177	CcSEcCtD
Roflumilast—Influenza—Doxorubicin—ovarian cancer	0.00157	0.00177	CcSEcCtD
Roflumilast—Palpitations—Docetaxel—ovarian cancer	0.00155	0.00174	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00154	0.00173	CcSEcCtD
Roflumilast—Weight decreased—Epirubicin—ovarian cancer	0.00153	0.00173	CcSEcCtD
Roflumilast—Insomnia—Paclitaxel—ovarian cancer	0.00153	0.00172	CcSEcCtD
Roflumilast—Pneumonia—Epirubicin—ovarian cancer	0.00152	0.00171	CcSEcCtD
Roflumilast—Infestation NOS—Epirubicin—ovarian cancer	0.00151	0.0017	CcSEcCtD
Roflumilast—Infestation—Epirubicin—ovarian cancer	0.00151	0.0017	CcSEcCtD
Roflumilast—Myalgia—Docetaxel—ovarian cancer	0.00149	0.00168	CcSEcCtD
Roflumilast—Nausea—Vinorelbine—ovarian cancer	0.00149	0.00168	CcSEcCtD
Roflumilast—Dyspepsia—Paclitaxel—ovarian cancer	0.00149	0.00167	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00148	0.00167	CcSEcCtD
Roflumilast—Urinary tract infection—Epirubicin—ovarian cancer	0.00147	0.00165	CcSEcCtD
Roflumilast—Decreased appetite—Paclitaxel—ovarian cancer	0.00147	0.00165	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00146	0.00164	CcSEcCtD
Roflumilast—Fatigue—Paclitaxel—ovarian cancer	0.00145	0.00164	CcSEcCtD
Roflumilast—Constipation—Paclitaxel—ovarian cancer	0.00144	0.00162	CcSEcCtD
Roflumilast—Hepatobiliary disease—Epirubicin—ovarian cancer	0.00143	0.00161	CcSEcCtD
Roflumilast—Infection—Docetaxel—ovarian cancer	0.00142	0.0016	CcSEcCtD
Roflumilast—Weight decreased—Doxorubicin—ovarian cancer	0.00142	0.0016	CcSEcCtD
Roflumilast—Sinusitis—Epirubicin—ovarian cancer	0.00142	0.0016	CcSEcCtD
Roflumilast—Pneumonia—Doxorubicin—ovarian cancer	0.00141	0.00158	CcSEcCtD
Roflumilast—Nervous system disorder—Docetaxel—ovarian cancer	0.0014	0.00158	CcSEcCtD
Roflumilast—Infestation NOS—Doxorubicin—ovarian cancer	0.0014	0.00157	CcSEcCtD
Roflumilast—Infestation—Doxorubicin—ovarian cancer	0.0014	0.00157	CcSEcCtD
Roflumilast—Feeling abnormal—Paclitaxel—ovarian cancer	0.00139	0.00156	CcSEcCtD
Roflumilast—Skin disorder—Docetaxel—ovarian cancer	0.00139	0.00156	CcSEcCtD
Roflumilast—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00138	0.00155	CcSEcCtD
Roflumilast—Rhinitis—Epirubicin—ovarian cancer	0.00136	0.00153	CcSEcCtD
Roflumilast—Urinary tract infection—Doxorubicin—ovarian cancer	0.00136	0.00153	CcSEcCtD
Roflumilast—Urticaria—Paclitaxel—ovarian cancer	0.00134	0.00151	CcSEcCtD
Roflumilast—Connective tissue disorder—Epirubicin—ovarian cancer	0.00133	0.0015	CcSEcCtD
Roflumilast—Abdominal pain—Paclitaxel—ovarian cancer	0.00133	0.0015	CcSEcCtD
Roflumilast—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.00132	0.00149	CcSEcCtD
Roflumilast—Sinusitis—Doxorubicin—ovarian cancer	0.00131	0.00148	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.0013	0.00147	CcSEcCtD
Roflumilast—Insomnia—Docetaxel—ovarian cancer	0.00129	0.00145	CcSEcCtD
Roflumilast—Cardiac disorder—Epirubicin—ovarian cancer	0.00126	0.00142	CcSEcCtD
Roflumilast—Rhinitis—Doxorubicin—ovarian cancer	0.00126	0.00142	CcSEcCtD
Roflumilast—Dyspepsia—Docetaxel—ovarian cancer	0.00126	0.00142	CcSEcCtD
Roflumilast—Decreased appetite—Docetaxel—ovarian cancer	0.00124	0.0014	CcSEcCtD
Roflumilast—Hypersensitivity—Paclitaxel—ovarian cancer	0.00124	0.0014	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00123	0.00139	CcSEcCtD
Roflumilast—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00123	0.00139	CcSEcCtD
Roflumilast—Fatigue—Docetaxel—ovarian cancer	0.00123	0.00139	CcSEcCtD
Roflumilast—Immune system disorder—Epirubicin—ovarian cancer	0.00123	0.00138	CcSEcCtD
Roflumilast—Mediastinal disorder—Epirubicin—ovarian cancer	0.00122	0.00138	CcSEcCtD
Roflumilast—Constipation—Docetaxel—ovarian cancer	0.00122	0.00138	CcSEcCtD
Roflumilast—Asthenia—Paclitaxel—ovarian cancer	0.00121	0.00136	CcSEcCtD
Roflumilast—Mental disorder—Epirubicin—ovarian cancer	0.00119	0.00134	CcSEcCtD
Roflumilast—Malnutrition—Epirubicin—ovarian cancer	0.00118	0.00133	CcSEcCtD
Roflumilast—Feeling abnormal—Docetaxel—ovarian cancer	0.00118	0.00133	CcSEcCtD
Roflumilast—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00117	0.00132	CcSEcCtD
Roflumilast—Cardiac disorder—Doxorubicin—ovarian cancer	0.00117	0.00131	CcSEcCtD
Roflumilast—Tension—Epirubicin—ovarian cancer	0.00116	0.0013	CcSEcCtD
Roflumilast—Dysgeusia—Epirubicin—ovarian cancer	0.00116	0.0013	CcSEcCtD
Roflumilast—Diarrhoea—Paclitaxel—ovarian cancer	0.00115	0.0013	CcSEcCtD
Roflumilast—Nervousness—Epirubicin—ovarian cancer	0.00115	0.00129	CcSEcCtD
Roflumilast—Back pain—Epirubicin—ovarian cancer	0.00114	0.00129	CcSEcCtD
Roflumilast—Muscle spasms—Epirubicin—ovarian cancer	0.00114	0.00128	CcSEcCtD
Roflumilast—Immune system disorder—Doxorubicin—ovarian cancer	0.00113	0.00128	CcSEcCtD
Roflumilast—Mediastinal disorder—Doxorubicin—ovarian cancer	0.00113	0.00127	CcSEcCtD
Roflumilast—Abdominal pain—Docetaxel—ovarian cancer	0.00113	0.00127	CcSEcCtD
Roflumilast—Dizziness—Paclitaxel—ovarian cancer	0.00112	0.00125	CcSEcCtD
Roflumilast—Mental disorder—Doxorubicin—ovarian cancer	0.0011	0.00124	CcSEcCtD
Roflumilast—Ill-defined disorder—Epirubicin—ovarian cancer	0.0011	0.00123	CcSEcCtD
Roflumilast—Malnutrition—Doxorubicin—ovarian cancer	0.00109	0.00123	CcSEcCtD
Roflumilast—Tension—Doxorubicin—ovarian cancer	0.00107	0.00121	CcSEcCtD
Roflumilast—Vomiting—Paclitaxel—ovarian cancer	0.00107	0.00121	CcSEcCtD
Roflumilast—Dysgeusia—Doxorubicin—ovarian cancer	0.00107	0.0012	CcSEcCtD
Roflumilast—Malaise—Epirubicin—ovarian cancer	0.00107	0.0012	CcSEcCtD
Roflumilast—Rash—Paclitaxel—ovarian cancer	0.00106	0.0012	CcSEcCtD
Roflumilast—Dermatitis—Paclitaxel—ovarian cancer	0.00106	0.0012	CcSEcCtD
Roflumilast—Nervousness—Doxorubicin—ovarian cancer	0.00106	0.00119	CcSEcCtD
Roflumilast—Vertigo—Epirubicin—ovarian cancer	0.00106	0.00119	CcSEcCtD
Roflumilast—Back pain—Doxorubicin—ovarian cancer	0.00106	0.00119	CcSEcCtD
Roflumilast—Headache—Paclitaxel—ovarian cancer	0.00106	0.00119	CcSEcCtD
Roflumilast—Hypersensitivity—Docetaxel—ovarian cancer	0.00105	0.00118	CcSEcCtD
Roflumilast—Muscle spasms—Doxorubicin—ovarian cancer	0.00105	0.00118	CcSEcCtD
Roflumilast—Palpitations—Epirubicin—ovarian cancer	0.00104	0.00117	CcSEcCtD
Roflumilast—Asthenia—Docetaxel—ovarian cancer	0.00103	0.00115	CcSEcCtD
Roflumilast—Ill-defined disorder—Doxorubicin—ovarian cancer	0.00101	0.00114	CcSEcCtD
Roflumilast—Myalgia—Epirubicin—ovarian cancer	0.00101	0.00113	CcSEcCtD
Roflumilast—Anxiety—Epirubicin—ovarian cancer	0.001	0.00113	CcSEcCtD
Roflumilast—Nausea—Paclitaxel—ovarian cancer	0.001	0.00113	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000999	0.00112	CcSEcCtD
Roflumilast—Discomfort—Epirubicin—ovarian cancer	0.000994	0.00112	CcSEcCtD
Roflumilast—Malaise—Doxorubicin—ovarian cancer	0.000986	0.00111	CcSEcCtD
Roflumilast—Vertigo—Doxorubicin—ovarian cancer	0.000982	0.0011	CcSEcCtD
Roflumilast—Diarrhoea—Docetaxel—ovarian cancer	0.000978	0.0011	CcSEcCtD
Roflumilast—Palpitations—Doxorubicin—ovarian cancer	0.000966	0.00109	CcSEcCtD
Roflumilast—Infection—Epirubicin—ovarian cancer	0.000958	0.00108	CcSEcCtD
Roflumilast—Nervous system disorder—Epirubicin—ovarian cancer	0.000946	0.00106	CcSEcCtD
Roflumilast—Dizziness—Docetaxel—ovarian cancer	0.000946	0.00106	CcSEcCtD
Roflumilast—Skin disorder—Epirubicin—ovarian cancer	0.000937	0.00105	CcSEcCtD
Roflumilast—Myalgia—Doxorubicin—ovarian cancer	0.000931	0.00105	CcSEcCtD
Roflumilast—Anxiety—Doxorubicin—ovarian cancer	0.000928	0.00104	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000925	0.00104	CcSEcCtD
Roflumilast—Discomfort—Doxorubicin—ovarian cancer	0.00092	0.00103	CcSEcCtD
Roflumilast—Vomiting—Docetaxel—ovarian cancer	0.000909	0.00102	CcSEcCtD
Roflumilast—Rash—Docetaxel—ovarian cancer	0.000902	0.00101	CcSEcCtD
Roflumilast—Dermatitis—Docetaxel—ovarian cancer	0.000901	0.00101	CcSEcCtD
Roflumilast—Headache—Docetaxel—ovarian cancer	0.000896	0.00101	CcSEcCtD
Roflumilast—Infection—Doxorubicin—ovarian cancer	0.000887	0.000997	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000879	0.000988	CcSEcCtD
Roflumilast—Nervous system disorder—Doxorubicin—ovarian cancer	0.000875	0.000984	CcSEcCtD
Roflumilast—Insomnia—Epirubicin—ovarian cancer	0.000872	0.000981	CcSEcCtD
Roflumilast—Skin disorder—Doxorubicin—ovarian cancer	0.000867	0.000975	CcSEcCtD
Roflumilast—Nausea—Docetaxel—ovarian cancer	0.000849	0.000955	CcSEcCtD
Roflumilast—Dyspepsia—Epirubicin—ovarian cancer	0.000849	0.000955	CcSEcCtD
Roflumilast—Decreased appetite—Epirubicin—ovarian cancer	0.000838	0.000943	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000833	0.000937	CcSEcCtD
Roflumilast—Fatigue—Epirubicin—ovarian cancer	0.000832	0.000935	CcSEcCtD
Roflumilast—Constipation—Epirubicin—ovarian cancer	0.000825	0.000928	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000813	0.000914	CcSEcCtD
Roflumilast—Insomnia—Doxorubicin—ovarian cancer	0.000807	0.000908	CcSEcCtD
Roflumilast—Feeling abnormal—Epirubicin—ovarian cancer	0.000795	0.000894	CcSEcCtD
Roflumilast—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000789	0.000887	CcSEcCtD
Roflumilast—Dyspepsia—Doxorubicin—ovarian cancer	0.000786	0.000884	CcSEcCtD
Roflumilast—Decreased appetite—Doxorubicin—ovarian cancer	0.000776	0.000873	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00077	0.000867	CcSEcCtD
Roflumilast—Fatigue—Doxorubicin—ovarian cancer	0.000769	0.000865	CcSEcCtD
Roflumilast—Urticaria—Epirubicin—ovarian cancer	0.000766	0.000862	CcSEcCtD
Roflumilast—Constipation—Doxorubicin—ovarian cancer	0.000763	0.000858	CcSEcCtD
Roflumilast—Abdominal pain—Epirubicin—ovarian cancer	0.000762	0.000858	CcSEcCtD
Roflumilast—Feeling abnormal—Doxorubicin—ovarian cancer	0.000735	0.000827	CcSEcCtD
Roflumilast—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00073	0.000821	CcSEcCtD
Roflumilast—Hypersensitivity—Epirubicin—ovarian cancer	0.000711	0.000799	CcSEcCtD
Roflumilast—Urticaria—Doxorubicin—ovarian cancer	0.000709	0.000797	CcSEcCtD
Roflumilast—Abdominal pain—Doxorubicin—ovarian cancer	0.000705	0.000793	CcSEcCtD
Roflumilast—Asthenia—Epirubicin—ovarian cancer	0.000692	0.000778	CcSEcCtD
Roflumilast—Diarrhoea—Epirubicin—ovarian cancer	0.00066	0.000742	CcSEcCtD
Roflumilast—Hypersensitivity—Doxorubicin—ovarian cancer	0.000658	0.00074	CcSEcCtD
Roflumilast—Asthenia—Doxorubicin—ovarian cancer	0.00064	0.00072	CcSEcCtD
Roflumilast—Dizziness—Epirubicin—ovarian cancer	0.000638	0.000717	CcSEcCtD
Roflumilast—Vomiting—Epirubicin—ovarian cancer	0.000613	0.00069	CcSEcCtD
Roflumilast—Diarrhoea—Doxorubicin—ovarian cancer	0.000611	0.000687	CcSEcCtD
Roflumilast—Rash—Epirubicin—ovarian cancer	0.000608	0.000684	CcSEcCtD
Roflumilast—Dermatitis—Epirubicin—ovarian cancer	0.000608	0.000683	CcSEcCtD
Roflumilast—Headache—Epirubicin—ovarian cancer	0.000604	0.00068	CcSEcCtD
Roflumilast—Dizziness—Doxorubicin—ovarian cancer	0.00059	0.000664	CcSEcCtD
Roflumilast—Nausea—Epirubicin—ovarian cancer	0.000573	0.000644	CcSEcCtD
Roflumilast—Vomiting—Doxorubicin—ovarian cancer	0.000567	0.000638	CcSEcCtD
Roflumilast—Rash—Doxorubicin—ovarian cancer	0.000563	0.000633	CcSEcCtD
Roflumilast—Dermatitis—Doxorubicin—ovarian cancer	0.000562	0.000632	CcSEcCtD
Roflumilast—Headache—Doxorubicin—ovarian cancer	0.000559	0.000629	CcSEcCtD
Roflumilast—Nausea—Doxorubicin—ovarian cancer	0.00053	0.000596	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—PPP1CC—ovarian cancer	6.84e-05	0.00308	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HDAC6—ovarian cancer	6.76e-05	0.00304	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PPP2R1A—ovarian cancer	6.67e-05	0.003	CbGpPWpGaD
Roflumilast—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—ovarian cancer	6.36e-05	0.00286	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—YAP1—ovarian cancer	5.99e-05	0.00269	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HDAC6—ovarian cancer	5.89e-05	0.00265	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—XIAP—ovarian cancer	5.86e-05	0.00264	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PPP2R1A—ovarian cancer	5.81e-05	0.00261	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SMARCA4—ovarian cancer	5.71e-05	0.00257	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HDAC6—ovarian cancer	5.6e-05	0.00252	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EREG—ovarian cancer	5.58e-05	0.00251	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PPP2R1A—ovarian cancer	5.53e-05	0.00249	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PGR—ovarian cancer	5.23e-05	0.00235	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—YAP1—ovarian cancer	5.21e-05	0.00234	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HDAC6—ovarian cancer	5.19e-05	0.00233	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PPP2R1A—ovarian cancer	5.12e-05	0.0023	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—XIAP—ovarian cancer	5.11e-05	0.0023	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SMARCA4—ovarian cancer	4.98e-05	0.00224	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—YAP1—ovarian cancer	4.96e-05	0.00223	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CG—ovarian cancer	4.92e-05	0.00221	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—XIAP—ovarian cancer	4.86e-05	0.00219	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PARP1—ovarian cancer	4.86e-05	0.00219	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EREG—ovarian cancer	4.86e-05	0.00218	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SMARCA4—ovarian cancer	4.74e-05	0.00213	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6ST—ovarian cancer	4.65e-05	0.00209	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EREG—ovarian cancer	4.62e-05	0.00208	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—YAP1—ovarian cancer	4.59e-05	0.00206	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PGR—ovarian cancer	4.55e-05	0.00205	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—XIAP—ovarian cancer	4.5e-05	0.00202	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CG—ovarian cancer	4.47e-05	0.00201	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SMARCA4—ovarian cancer	4.38e-05	0.00197	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PGR—ovarian cancer	4.33e-05	0.00195	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CD—ovarian cancer	4.32e-05	0.00195	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CG—ovarian cancer	4.28e-05	0.00193	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EREG—ovarian cancer	4.28e-05	0.00192	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PARP1—ovarian cancer	4.23e-05	0.0019	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CG—ovarian cancer	4.08e-05	0.00183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6ST—ovarian cancer	4.05e-05	0.00182	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PARP1—ovarian cancer	4.03e-05	0.00181	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PGR—ovarian cancer	4.01e-05	0.0018	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PPP2R1A—ovarian cancer	3.94e-05	0.00177	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CD—ovarian cancer	3.93e-05	0.00177	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CG—ovarian cancer	3.89e-05	0.00175	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6ST—ovarian cancer	3.85e-05	0.00173	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CG—ovarian cancer	3.77e-05	0.0017	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CB—ovarian cancer	3.77e-05	0.0017	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CD—ovarian cancer	3.76e-05	0.00169	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PARP1—ovarian cancer	3.73e-05	0.00168	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CG—ovarian cancer	3.7e-05	0.00167	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—CXCL8—ovarian cancer	3.62e-05	0.00163	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CD—ovarian cancer	3.58e-05	0.00161	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6ST—ovarian cancer	3.56e-05	0.0016	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—IL2—ovarian cancer	3.46e-05	0.00156	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PPP2R1A—ovarian cancer	3.43e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CG—ovarian cancer	3.42e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CB—ovarian cancer	3.42e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CD—ovarian cancer	3.42e-05	0.00154	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CD—ovarian cancer	3.31e-05	0.00149	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—CXCL8—ovarian cancer	3.29e-05	0.00148	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CB—ovarian cancer	3.28e-05	0.00148	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PPP2R1A—ovarian cancer	3.27e-05	0.00147	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CD—ovarian cancer	3.25e-05	0.00146	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—CXCL8—ovarian cancer	3.15e-05	0.00142	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL2—ovarian cancer	3.14e-05	0.00141	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TERT—ovarian cancer	3.13e-05	0.00141	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CB—ovarian cancer	3.12e-05	0.0014	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PPP2R1A—ovarian cancer	3.02e-05	0.00136	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—IL2—ovarian cancer	3.01e-05	0.00136	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CD—ovarian cancer	3.01e-05	0.00135	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—CXCL8—ovarian cancer	3e-05	0.00135	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CB—ovarian cancer	2.98e-05	0.00134	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CAV1—ovarian cancer	2.9e-05	0.0013	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CB—ovarian cancer	2.89e-05	0.0013	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—IL2—ovarian cancer	2.87e-05	0.00129	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—CXCL8—ovarian cancer	2.86e-05	0.00129	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CB—ovarian cancer	2.84e-05	0.00128	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ESR1—ovarian cancer	2.79e-05	0.00126	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—CXCL8—ovarian cancer	2.78e-05	0.00125	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6ST—ovarian cancer	2.75e-05	0.00124	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL2—ovarian cancer	2.74e-05	0.00123	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TERT—ovarian cancer	2.73e-05	0.00123	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCL8—ovarian cancer	2.72e-05	0.00123	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—IL2—ovarian cancer	2.65e-05	0.00119	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APC—ovarian cancer	2.64e-05	0.00119	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CG—ovarian cancer	2.64e-05	0.00119	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—NRAS—ovarian cancer	2.64e-05	0.00119	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CB—ovarian cancer	2.62e-05	0.00118	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL2—ovarian cancer	2.6e-05	0.00117	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TERT—ovarian cancer	2.59e-05	0.00117	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK3—ovarian cancer	2.53e-05	0.00114	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CAV1—ovarian cancer	2.52e-05	0.00113	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL8—ovarian cancer	2.52e-05	0.00113	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ESR1—ovarian cancer	2.43e-05	0.00109	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL2—ovarian cancer	2.41e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK1—ovarian cancer	2.4e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—EGFR—ovarian cancer	2.4e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TERT—ovarian cancer	2.4e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CAV1—ovarian cancer	2.4e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6ST—ovarian cancer	2.39e-05	0.00108	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CD—ovarian cancer	2.32e-05	0.00104	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ESR1—ovarian cancer	2.31e-05	0.00104	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CA—ovarian cancer	2.3e-05	0.00103	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CG—ovarian cancer	2.3e-05	0.00103	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APC—ovarian cancer	2.3e-05	0.00103	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—NRAS—ovarian cancer	2.3e-05	0.00103	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6ST—ovarian cancer	2.28e-05	0.00102	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—KRAS—ovarian cancer	2.27e-05	0.00102	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CAV1—ovarian cancer	2.22e-05	0.000999	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK3—ovarian cancer	2.2e-05	0.00099	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CG—ovarian cancer	2.19e-05	0.000984	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APC—ovarian cancer	2.19e-05	0.000984	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—NRAS—ovarian cancer	2.19e-05	0.000984	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ESR1—ovarian cancer	2.14e-05	0.000963	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6ST—ovarian cancer	2.11e-05	0.000947	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK3—ovarian cancer	2.09e-05	0.000942	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK1—ovarian cancer	2.09e-05	0.000942	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—EGFR—ovarian cancer	2.09e-05	0.000941	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CA—ovarian cancer	2.09e-05	0.000939	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ERBB2—ovarian cancer	2.05e-05	0.000922	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CG—ovarian cancer	2.02e-05	0.00091	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APC—ovarian cancer	2.02e-05	0.00091	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—NRAS—ovarian cancer	2.02e-05	0.00091	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CB—ovarian cancer	2.02e-05	0.00091	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MTOR—ovarian cancer	2.02e-05	0.00091	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CD—ovarian cancer	2.02e-05	0.000908	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CA—ovarian cancer	2e-05	0.0009	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK1—ovarian cancer	1.99e-05	0.000896	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EGFR—ovarian cancer	1.99e-05	0.000896	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—KRAS—ovarian cancer	1.98e-05	0.000889	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL8—ovarian cancer	1.94e-05	0.000874	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK3—ovarian cancer	1.94e-05	0.000872	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—HRAS—ovarian cancer	1.93e-05	0.000868	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CD—ovarian cancer	1.92e-05	0.000865	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CA—ovarian cancer	1.9e-05	0.000856	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1B—ovarian cancer	1.9e-05	0.000854	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—KRAS—ovarian cancer	1.88e-05	0.000847	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—AKT1—ovarian cancer	1.88e-05	0.000844	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CASP3—ovarian cancer	1.86e-05	0.000837	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL2—ovarian cancer	1.86e-05	0.000835	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—ovarian cancer	1.85e-05	0.000831	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK1—ovarian cancer	1.84e-05	0.000829	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EGFR—ovarian cancer	1.84e-05	0.000829	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CA—ovarian cancer	1.82e-05	0.000817	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCND1—ovarian cancer	1.81e-05	0.000814	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CTNNB1—ovarian cancer	1.79e-05	0.000806	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ERBB2—ovarian cancer	1.78e-05	0.000802	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CD—ovarian cancer	1.78e-05	0.0008	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CA—ovarian cancer	1.76e-05	0.000792	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MTOR—ovarian cancer	1.76e-05	0.000792	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CB—ovarian cancer	1.76e-05	0.000792	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP9—ovarian cancer	1.76e-05	0.000791	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTEN—ovarian cancer	1.75e-05	0.000786	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—KRAS—ovarian cancer	1.74e-05	0.000783	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CA—ovarian cancer	1.73e-05	0.000778	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKT1—ovarian cancer	1.7e-05	0.000767	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB2—ovarian cancer	1.7e-05	0.000764	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL8—ovarian cancer	1.69e-05	0.000761	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—HRAS—ovarian cancer	1.68e-05	0.000756	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CB—ovarian cancer	1.68e-05	0.000754	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MTOR—ovarian cancer	1.68e-05	0.000754	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1B—ovarian cancer	1.65e-05	0.000743	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKT1—ovarian cancer	1.63e-05	0.000735	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CASP3—ovarian cancer	1.62e-05	0.000728	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2—ovarian cancer	1.62e-05	0.000727	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL8—ovarian cancer	1.61e-05	0.000724	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—ovarian cancer	1.61e-05	0.000724	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CA—ovarian cancer	1.6e-05	0.00072	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—HRAS—ovarian cancer	1.6e-05	0.00072	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—ovarian cancer	1.58e-05	0.00071	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCND1—ovarian cancer	1.58e-05	0.000709	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1B—ovarian cancer	1.57e-05	0.000707	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB2—ovarian cancer	1.57e-05	0.000707	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—STAT3—ovarian cancer	1.56e-05	0.000703	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CTNNB1—ovarian cancer	1.56e-05	0.000702	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NRAS—ovarian cancer	1.56e-05	0.000701	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKT1—ovarian cancer	1.56e-05	0.0007	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MTOR—ovarian cancer	1.55e-05	0.000697	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CB—ovarian cancer	1.55e-05	0.000697	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CASP3—ovarian cancer	1.54e-05	0.000693	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2—ovarian cancer	1.54e-05	0.000692	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—ovarian cancer	1.53e-05	0.000689	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP9—ovarian cancer	1.53e-05	0.000688	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTEN—ovarian cancer	1.52e-05	0.000684	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCND1—ovarian cancer	1.5e-05	0.000675	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK3—ovarian cancer	1.49e-05	0.000672	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL8—ovarian cancer	1.49e-05	0.00067	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CTNNB1—ovarian cancer	1.49e-05	0.000668	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AKT1—ovarian cancer	1.48e-05	0.000667	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—HRAS—ovarian cancer	1.48e-05	0.000666	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP9—ovarian cancer	1.46e-05	0.000655	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1B—ovarian cancer	1.45e-05	0.000654	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—ovarian cancer	1.45e-05	0.000653	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTEN—ovarian cancer	1.45e-05	0.000651	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AKT1—ovarian cancer	1.44e-05	0.000647	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CASP3—ovarian cancer	1.43e-05	0.000641	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2—ovarian cancer	1.42e-05	0.00064	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK1—ovarian cancer	1.42e-05	0.000639	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGFR—ovarian cancer	1.42e-05	0.000639	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—ovarian cancer	1.42e-05	0.000637	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKT1—ovarian cancer	1.41e-05	0.000635	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCND1—ovarian cancer	1.39e-05	0.000624	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CTNNB1—ovarian cancer	1.37e-05	0.000618	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—ovarian cancer	1.37e-05	0.000618	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—STAT3—ovarian cancer	1.36e-05	0.000612	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NRAS—ovarian cancer	1.36e-05	0.00061	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP9—ovarian cancer	1.35e-05	0.000606	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KRAS—ovarian cancer	1.34e-05	0.000604	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTEN—ovarian cancer	1.34e-05	0.000603	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—ovarian cancer	1.31e-05	0.000588	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKT1—ovarian cancer	1.31e-05	0.000588	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK3—ovarian cancer	1.3e-05	0.000585	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—STAT3—ovarian cancer	1.29e-05	0.000582	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NRAS—ovarian cancer	1.29e-05	0.000581	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—ovarian cancer	1.26e-05	0.000569	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK3—ovarian cancer	1.24e-05	0.000556	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK1—ovarian cancer	1.24e-05	0.000556	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGFR—ovarian cancer	1.24e-05	0.000556	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CA—ovarian cancer	1.23e-05	0.000554	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—ovarian cancer	1.21e-05	0.000544	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—ovarian cancer	1.2e-05	0.000541	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—STAT3—ovarian cancer	1.2e-05	0.000539	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NRAS—ovarian cancer	1.19e-05	0.000538	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TP53—ovarian cancer	1.19e-05	0.000536	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK1—ovarian cancer	1.18e-05	0.000529	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGFR—ovarian cancer	1.18e-05	0.000529	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KRAS—ovarian cancer	1.17e-05	0.000525	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK3—ovarian cancer	1.14e-05	0.000515	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HRAS—ovarian cancer	1.14e-05	0.000513	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—ovarian cancer	1.11e-05	0.000501	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KRAS—ovarian cancer	1.11e-05	0.0005	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—ovarian cancer	1.09e-05	0.000491	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK1—ovarian cancer	1.09e-05	0.00049	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGFR—ovarian cancer	1.09e-05	0.00049	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CA—ovarian cancer	1.07e-05	0.000483	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TP53—ovarian cancer	1.04e-05	0.000467	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KRAS—ovarian cancer	1.03e-05	0.000463	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CA—ovarian cancer	1.02e-05	0.000459	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT1—ovarian cancer	1.01e-05	0.000453	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HRAS—ovarian cancer	9.93e-06	0.000447	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TP53—ovarian cancer	9.88e-06	0.000444	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—ovarian cancer	9.5e-06	0.000427	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CA—ovarian cancer	9.45e-06	0.000425	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HRAS—ovarian cancer	9.45e-06	0.000425	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TP53—ovarian cancer	9.14e-06	0.000411	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—ovarian cancer	9.04e-06	0.000407	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT1—ovarian cancer	8.76e-06	0.000394	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HRAS—ovarian cancer	8.74e-06	0.000393	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—ovarian cancer	8.37e-06	0.000376	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT1—ovarian cancer	8.34e-06	0.000375	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT1—ovarian cancer	7.72e-06	0.000347	CbGpPWpGaD
